Fifth Third Bancorp Buys 906 Shares of Hims & Hers Health, Inc. $HIMS

Fifth Third Bancorp grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 58.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,448 shares of the company’s stock after purchasing an additional 906 shares during the period. Fifth Third Bancorp’s holdings in Hims & Hers Health were worth $122,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the first quarter worth about $30,000. UMB Bank n.a. boosted its stake in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after acquiring an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the first quarter worth about $41,000. Larson Financial Group LLC boosted its stake in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after acquiring an additional 458 shares in the last quarter. Finally, Webster Bank N. A. boosted its stake in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after acquiring an additional 630 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Activity

In other news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares of the company’s stock, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,622,727 shares of company stock valued at $83,566,691 over the last three months. Insiders own 13.71% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the topic of several research reports. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial decreased their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Finally, Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Stock Down 0.8%

HIMS opened at $56.27 on Thursday. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a 50 day moving average price of $51.55 and a 200-day moving average price of $46.86. Hims & Hers Health, Inc. has a twelve month low of $16.05 and a twelve month high of $72.98. The stock has a market capitalization of $12.72 billion, a price-to-earnings ratio of 70.33, a PEG ratio of 3.83 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the previous year, the firm earned $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.